ProQR Therapeutics N.V. PRQR
Set alert
1.32 USD 0.00 0.00%
At close
1.43 +0.11 +8.70%
Pre-market · Nov 3, 7:29 AM ET
1.31 Day range 1.45
1.20 52-week range 2.65
- YTD
- -34.65%
- 1 year
- -49.03%
- Open
- 1.39
- Prev close
- 1.32
- Mkt cap
- 186.28M
- Vol
- 644.20K
- Avg vol
- 856.95K
- EPS
- -0.45
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.31
- High
- 1.45
- Forward P/E
- -5.68
- Beta
- 0.25
- Short ratio
- 0.31
- Inst. own
- 24.96%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.44
- 200-d avg
- 2.32
- 1y target
- 8.00
Analyst view
Consensus: buy
Buy
Price target (mean) 8.00 +506.1% upside
Now 1.32
- Target (low)
- 4.00
- Target (mean)
- 8.00
- Target (high)
- 14.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy2
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.148 | -0.148 – -0.148 | -0.07643 | -93.6% | 6.97M | +2.8% | 1 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 8.99M | +79.1% | 0 |
| Current year | -0.482 | -0.482 – -0.482 | -0.41893 | -15.1% | 22.86M | +119.8% | 1 |
| Next year | -0.551 | -0.551 – -0.551 | -0.482 | -14.3% | 16.70M | -26.9% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Dec 12, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 29, 2024 | Raymond James | Upgrade | Outperform | Strong Buy |
| May 10, 2024 | Chardan Capital | Maintained | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 18, 2024 | Citigroup | Maintained | Neutral | Neutral |
| Mar 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 14, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 8, 2023 | Raymond James | Maintained | Outperform | Outperform |
| Nov 8, 2023 | Chardan Capital | Upgrade | Neutral | Buy |
| Sep 18, 2023 | Citigroup | Maintained | Buy | Buy |
| Aug 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 4, 2023 | Chardan Capital | Reiterated | Neutral | Neutral |
| May 17, 2023 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| May 17, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 17, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 30, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| Mar 30, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Dec 23, 2022 | Raymond James | Maintained | — | Outperform |
| Dec 22, 2022 | Cantor Fitzgerald | Upgrade | Neutral | Overweight |
| Aug 15, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 12, 2022 | Chardan Capital | Downgrade | Buy | Neutral |
| Aug 12, 2022 | Raymond James | Upgrade | Market Perform | Outperform |
| May 9, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 6, 2022 | Chardan Capital | Maintained | — | Buy |
| Apr 14, 2022 | Chardan Capital | Maintained | — | Buy |
| Apr 14, 2022 | JMP Securities | Maintained | — | Market Outperform |
| Feb 14, 2022 | Chardan Capital | Maintained | — | Buy |